About

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

Morphogenesis Website

Access Webcast Replay

Harnessing the Therapeutic Potential of Mitochondrial DNA

CohBar is a clinical-stage biotechnology company exploiting the power of the mitochondria and its encoded peptides to develop potential breakthrough therapeutics targeting chronic and age-related diseases. While extensive work has been conducted on the nuclear genome, we are the first to discover potential therapeutics sourced from the mitochondrial genome.

We developed our technology platform to enable us to identify and develop peptides that we believe have promise as potential human therapeutics. One of the key early insights that led to the development of CohBar’s novel platform was the recognition that certain mitochondrially encoded peptides produce effects that are not limited to local regulation within the mitochondria and may have important roles to play in critical systemic biological pathways quite distinct from what has traditionally been thought of as mitochondrial function.

As the first company to mine the mitochondrial genome for therapeutically relevant peptides, we have established a robust IP portfolio.

View Pipeline

Serving Patients with Unmet Medical Needs

Our unique technology offers a differentiated approach to treating a wide range diseases.

View Patient Resources

An emerging epidemic, NASH is projected to affect 27 million U.S. adults by 2030. NASH is a progressive liver disease that is one of the leading causes of cirrhosis in the United States. It is associated with a variety of metabolic disorders, including diabetes, obesity, and lipid abnormalities. There is currently no approved treatment.

Learn More About NASH

Obesity impacts more than 40% of U.S. adults and is a major risk factor for a variety of other serious diseases, including heart disease, stroke, type 2 diabetes, NASH and certain types of cancer.

Learn More About Obesity

IPF is a chronic, progressive, debilitating, and usually fatal interstitial lung disease that affects approximately 100,000 people in the U.S. This orphan disease results in fibrotic scarring of the lungs. Current treatment options are limited and poorly tolerated.

Learn More About IPF

A Powerhouse Leadership Team

Our leadership team is comprised of experienced scientists, doctors, and biotech executives.

View Management Team View Board of Directors